Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02572245 | A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects | PHASE1 | COMPLETED | 164 | — | — | Jan 1, 2016 | May 1, 2016 | Jun 6, 2016 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| PF-06410293 PFS (Prefilled Syringe) | ACTIVE_COMPARATOR | PF-06410293 40 mg administered by Prefilled Syringe (PFS) |
| PF-06410293 PFP (Prefilled Pen) | ACTIVE_COMPARATOR | PF-06410293 40 mg administered by Prefilled pen |
| Name | Type | Description |
|---|---|---|
| PF-06410293 PFS | DEVICE | PF-06410293 40 mg administered subcutaneously by Prefilled syringe |
| PF-06410293 PFP | DEVICE | PF-06410293 40 mg administered subcutaneously by prefilled pen |
Inclusion Criteria: 1. Healthy female subjects and/or male subjects, who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood ...